Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Other

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

By The Northwire Desk — AI Analysis Dec 15, 2025 · 17:30 HBP · 2.05 HELIX BIOPHARMA CORP.
HBP · Price

Executive Summary

  • Helix BioPharma Corp. announced the filing of its unaudited interim financial statements for the three‑month period ended October 31, 2025, together with the accompanying MD&A and CEO/CFO certifications.
  • The filings are now publicly available on the company’s SEDAR+ profile and corporate website.
  • No additional operational or commercial updates were disclosed in this release.

Key Details

  • Interim Financial Statements: Unaudited statements for Q3 2025 (three‑month period ended 31 Oct 2025).
  • Management Discussion & Analysis (MD&A): Included with the interim filings, providing narrative context to the financial results.
  • CEO & CFO Certifications: Both executives have signed certifications confirming the accuracy of the interim statements and MD&A.
  • Access: Documents can be accessed at www.sedarplus.ca and https://www.helixbiopharma.com/filings-and-financials/.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from HELIX BIOPHARMA CORP.

Jun 12, 2026 · 18:15

Helix Biopharma Secures $3.67M Lifeline via Convertible Debentures, Cuts Losses as It Winds Down Pancreatic Trial

Earnings Mar 16, 2026 · 17:00

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Earnings Feb 24, 2026 · 09:00

Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

Other Feb 05, 2026 · 16:30

Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

M&A / Property Oct 29, 2025 · 12:45

Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results

Earnings Sep 05, 2025 · 18:54

Helix ends review, drops GEM equity facility plan

Financings